Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
US Army
Fish and Richardson
Express Scripts
Chubb
Farmers Insurance
Fuji
UBS
Argus Health

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DEXTROAMPHETAMINE SULFATE

« Back to Dashboard

Clinical Trials for Dextroamphetamine Sulfate

Trial ID Title Status Sponsor Phase Summary
NCT00000304 Dextroamphetamine as an Adjunct in Cocaine Treatment - 1 Completed University of Texas Phase 2 The purpose of this study is to evaluate dextroamphetamine sulfate (sustained release) as an adjunct in cocaine treatment; an evaluation of the ""replacement"" strategy.
NCT00000304 Dextroamphetamine as an Adjunct in Cocaine Treatment - 1 Completed National Institute on Drug Abuse (NIDA) Phase 2 The purpose of this study is to evaluate dextroamphetamine sulfate (sustained release) as an adjunct in cocaine treatment; an evaluation of the ""replacement"" strategy.
NCT00000306 Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3 Completed University of Texas Phase 2 The purpose of this study is to evaluate dextroamphetamine sulfate (sustained release) as an adjunct in concurrent cocaine and opiate dependent patients.
NCT00000306 Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3 Completed National Institute on Drug Abuse (NIDA) Phase 2 The purpose of this study is to evaluate dextroamphetamine sulfate (sustained release) as an adjunct in concurrent cocaine and opiate dependent patients.
NCT01886469 A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD) Completed Ironshore Pharmaceuticals and Development, Inc Phase 1/Phase 2 The main purpose of this study is to determine the rate and extent of absorption of one or more modified release formulations of amphetamine (HLD100) in both adolescents and children with ADHD.
NCT02884544 A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With Attention-Deficit/Hyperactivity Disorder Not yet recruiting Ironshore Pharmaceuticals and Development, Inc Phase 2 The phase 2 study will evaluate the safety, tolerability and efficacy of HLD100 at steady state (following up to 5 weeks of treatment) in children using an outpatient, single-center, open-label, flexible dose-escalation study design.
NCT02952196 Cannabidiol as a New Intervention for Amphetamine Dependence Not yet recruiting Centre hospitalier de l'Université de Montréal (CHUM) Phase 2 Addiction to amphetamine is characterized by alternating phases of intoxication and short abstinence, followed by recurrent drug-craving episodes which result in distress and relapse. Addiction involves a number of neurotransmission systems, including the endocannabinoid system (ECBS). Cannabidiol (CBD), the second most abundant component of cannabis, is known for its broad spectrum of physiological, anxiolytic and neuroprotective properties. It has been shown to have multiple therapeutic properties for treating anxiety, schizophrenia and interestingly CBD has been shown to be potentially helpful in treating addiction, due to its effects on various neuronal circuits involved in this disorder. The investigators overall hypothesis is that CBD is an interesting pharmacological contender to decrease amphetamine craving and treat amphetamine addiction.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Dextroamphetamine Sulfate

Condition Name

Condition Name for Dextroamphetamine Sulfate
Intervention Trials
Cocaine-Related Disorders 2
Schizophrenia 1
Psychosis 1
Opioid-Related Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Dextroamphetamine Sulfate
Intervention Trials
Disease 4
Hyperkinesis 2
Attention Deficit Disorder with Hyperactivity 2
Cocaine-Related Disorders 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Dextroamphetamine Sulfate

Trials by Country

Trials by Country for Dextroamphetamine Sulfate
Location Trials
United States 3
Canada 1
Austria 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Dextroamphetamine Sulfate
Location Trials
Texas 2
Nevada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Dextroamphetamine Sulfate

Clinical Trial Phase

Clinical Trial Phase for Dextroamphetamine Sulfate
Clinical Trial Phase Trials
Phase 2 4
Phase 1/Phase 2 1
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Dextroamphetamine Sulfate
Clinical Trial Phase Trials
Completed 3
Not yet recruiting 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Dextroamphetamine Sulfate

Sponsor Name

Sponsor Name for Dextroamphetamine Sulfate
Sponsor Trials
Ironshore Pharmaceuticals and Development, Inc 2
National Institute on Drug Abuse (NIDA) 2
University of Texas 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Dextroamphetamine Sulfate
Sponsor Trials
Other 6
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Fish and Richardson
Cantor Fitzgerald
Covington
Federal Trade Commission
Deloitte
McKinsey
Teva
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.